ArticleJournal of translational medicine2026
HOXD10 promotes hepatocellular carcinoma progression by enhancing m6A methylation and activating the PI3K/AKT/mTOR pathway.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Homeobox (HOX) gene family is capable of binding to specific deoxyribonucleic acid (DNA) sequences, thereby modulating gene expression through activation or repression, which subsequently influences cellular behaviors including proliferation, adhesion, differentiation, and metastasis. Nevertheless, the role of Homeobox D10 (HOXD10) in the prognosis and progression of hepatocellular carcinoma (HCC) remains to be elucidated.
methodsThe expression of HOXD10 in HCC was subsequently validated through Western blot and immunohistochemistry analysis. The functional role of HOXD10 in HCC was evaluated using a combination of high- and low-expression experiments, incorporating both in vitro and in vivo methodologies. Furthermore, The Cancer Genome Atlas (TCGA) database was employed to investigate the functional networks related to HOXD10. The research specifically investigated the relationship between HOXD10 expression and cancer stem cells (CSCs), emphasizing the role of N6-methyladenosine (m6A) methylation and the PI3K/AKT/mTOR signaling pathway in hepatocellular carcinoma (HCC).
resultsThe marked upregulation of HOXD10 expression in HCC suggests its potential impact on adverse prognostic outcomes. Furthermore, HOXD10 expression exhibited a significant association with the T stage, vascular invasion, and histological grade of HCC. Elevated HOXD10 expression was found to significantly enhance HCC cell proliferation, invasion, and migration. Notably, there was a significant correlation between HOXD10 expression and the activation of m6A methylation, as well as the PI3K/AKT/mTOR signaling pathway.
conclusionThe results of this study corroborate the hypothesis that HOXD10 serves as a novel biomarker for tumor progression in HCC. Furthermore, HOXD10 has the capacity to activate the PI3K/AKT/mTOR signaling pathway through the regulation of m6A RNA methylation levels, thereby facilitating the self-renewal of hepatic cancer stem cells (HCSCs).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.